Journal of Frontiers in Multidisciplinary Research

Innovative Strategies for Reducing Antimicrobial Resistance: A Review of Global Policy and Practice

Tolulope Olagoke Kolawole [1*], Ashiata Yetunde Mustapha [2], Akachukwu Obianuju Mbata [3], Busayo Olamide Tomoh [4], Adelaide Yeboah Forkuo [5], MariaTheresa Chinyeaka Kelvin-Agwu [6]

[1] Independent Researcher, Richmond, Virginia, USA
[2] Kwara State Ministry of Health, Nigeria
[3] Kaybat Pharmacy and Stores, Benin, Nigeria
[4] Independent Researcher, Cleveland, Ohio, USA
[5] Independent Researcher, USA
[6] Independent Researcher, Bolton, Greater Manchester, United Kingdom

* Corresponding Author: **Tolulope Olagoke Kolawole**

Article Info

E-ISSN: 3050-9726
P-ISSN: 3050-9718
Volume: 04
Issue: 01
January-June 2023
Received: 16-12-2022
Accepted: 14-01-2023
Published: 05-02-2023
Page No: 25-38

Abstract

Antimicrobial resistance (AMR) is a growing global health crisis, threatening the effectiveness of antibiotics and other antimicrobial agents. The widespread misuse and overuse of antibiotics in healthcare, agriculture, and animal husbandry have accelerated the emergence of resistant pathogens, leading to increased morbidity, mortality, and economic burdens. This review critically examines existing global policies and best practices aimed at curbing AMR while proposing innovative, actionable strategies to mitigate its impact. The study explores the effectiveness of national and international AMR action plans, including the World Health Organization's Global Action Plan (WHO-GAP) and country-specific frameworks such as the U.S. National Action Plan for Combating Antibiotic-Resistant Bacteria and the European One Health Action Plan against AMR. It evaluates regulatory policies, antibiotic stewardship programs, surveillance systems, and public awareness campaigns designed to promote responsible antimicrobial use. Key innovations in AMR reduction include the use of artificial intelligence (AI) and big data analytics for early detection of resistance patterns, precision medicine for targeted antimicrobial therapies, and the development of novel antibiotic alternatives such as bacteriophages and antimicrobial peptides. Additionally, advancements in rapid diagnostic tools and blockchain-based supply chain monitoring are examined for their potential to improve antimicrobial governance and reduce counterfeit medications. Challenges in implementing AMR policies, including regulatory fragmentation, lack of global coordination, and economic constraints, are discussed. The review highlights the need for interdisciplinary collaboration between governments, healthcare providers, pharmaceutical industries, and agricultural sectors to enforce stricter antimicrobial regulations, promote research and development of new treatments, and improve infection prevention measures. Findings suggest that a multifaceted approach integrating policy reforms, technological innovations, and public engagement is essential to slowing AMR progression. Strengthening surveillance networks, incentivizing antibiotic research, and enforcing antibiotic stewardship across all sectors can significantly reduce antimicrobial misuse and resistance. This review provides a roadmap for policymakers and stakeholders to develop sustainable, evidence-based AMR mitigation strategies.

DOI: https://doi.org/10.54660/.IJFMR.2023.4.1.25-38

Keywords: Antimicrobial Resistance, Antibiotic Stewardship, AMR Policy, One Health Approach, Rapid Diagnostics, Precision Medicine, Big Data in Healthcare, Artificial Intelligence, Global Health Governance, Novel Antimicrobial Therapies

1. Introduction

Antimicrobial resistance (AMR) has emerged as a critical global health threat, impacting public health, healthcare systems, and economies worldwide. The World Health Organization (WHO) has recognized AMR as one of the most significant health challenges of the 21st century, warning that infections that were once easily treatable may become life-threatening due to the rise of resistant bacteria, viruses, fungi, and parasites (Al Zoubi, *et al*, 2022, Kim *et al*, 2016). The misuse and overuse of antibiotics across human medicine, agriculture, and animal husbandry are primary contributors to this dilemma (Amafah, *et al*, 2023; Pierce *et al*, 2020). Studies show that countries with high antibiotic consumption, particularly in low- and middle-income settings, face significant challenges due to inadequate antimicrobial stewardship practices and lack of resources to implement effective interventions (Pierce *et al*, 2020; Ahmed *et al*, 2021).

The consequences of AMR are significant; patients with antibiotic-resistant infections often endure longer hospital stays and face increased healthcare costs, alongside a higher risk of morbidity and mortality when compared to those with treatable infections (Schiaffino *et al*, 2022). Projections indicate that, if AMR remains unaddressed, it could result in millions of deaths annually by 2050 Pierce *et al* (2020). Furthermore, public health advancements achieved over decades could be undermined, leading to a resurgence of infections that were previously controlled through effective antimicrobial therapies (Atta, *et al*, 2021, Kim *et al*, 2016). The economic burden associated with AMR not only strains healthcare systems but also exacerbates existing health disparities, particularly in lower-resource settings (Pierce *et al*, 2020).

Given the multitude of causes behind AMR, a coordinated global response is necessary. Effective antibiotic stewardship programs (ASPs) have been identified as essential strategies to reduce inappropriate prescribing and improve the quality of antibiotic use (Schiaffino *et al*, 2022; Kissler *et al*, 2020). These programs have documented success in various healthcare settings; for instance, initiatives focused on educating healthcare professionals about best practices in antibiotic prescribing have significantly reduced unnecessary antibiotic use (Ahmed *et al*, 2021; Timbrook *et al*, 2016). Additionally, governmental policy interventions are crucial to enforce regulations that mitigate antibiotic misuse across agricultural sectors, which are often less monitored (Ayo-Farai, *et al*, 2023, Katwyk *et al*, 2019).

Innovative strategies for combating AMR extend beyond healthcare settings and require diverse approaches, including education and awareness campaigns for the public, enhanced infection control practices, and the integration of antimicrobial stewardship into clinical practices (Atif & Tufail, 2022; Pakyz *et al*, 2014). Surveillance and reporting systems are vital for tracking antibiotic consumption patterns and resistance trends, enabling prompt and evidence-based responses (Karavolias *et al*, 2018). Moreover, international collaborations can facilitate the sharing of best practices and resources, ensuring that countries facing severe AMR challenges can implement effective interventions tailored to their specific contexts (Pierce *et al*, 2020).

In summary, addressing AMR represents an urgent, multifaceted challenge that requires the commitment of global health stakeholders to implement comprehensive and sustainable strategies. The interplay between education, policy, stewardship programs, and international cooperation is critical in mitigating the risks associated with antimicrobial resistance, thus safeguarding public health for future generations (Babarinde, *et al*, 2018).

2. Methodology

This study adopts the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology to conduct a comprehensive review of global policy and practice strategies for reducing antimicrobial resistance (AMR). The systematic review is designed to provide a structured synthesis of existing literature and evaluate the effectiveness of interventions implemented worldwide to mitigate the AMR crisis.

The search strategy was developed based on predefined eligibility criteria, ensuring that only relevant peer-reviewed articles, reviews, and policy documents were included. The databases searched included PubMed, Scopus, Web of Science, and Google Scholar. The search terms utilized included "antimicrobial resistance," "antibiotic stewardship," "AMR policy interventions," "global AMR strategies," and "national action plans on AMR." Boolean operators such as "AND," "OR," and "NOT" were employed to refine the search and eliminate irrelevant studies. Grey literature, including reports from international organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), was also considered.

The inclusion criteria for this review consisted of studies published in English within the last ten years, focusing on antimicrobial stewardship interventions, national and international policy initiatives, and innovative strategies to combat AMR. Studies that provided empirical evidence, systematic reviews, and meta-analyses were prioritized. Exclusion criteria included studies that did not explicitly address AMR policy or practice, non-peer-reviewed articles, and studies with limited data availability.

After the initial search, duplicate records were identified and removed using reference management software. The remaining studies underwent a title and abstract screening process by two independent reviewers to ensure relevance. Studies that met the inclusion criteria proceeded to full-text review, during which detailed assessments were conducted based on study design, objectives, outcomes, and findings. Discrepancies in study selection were resolved through consensus discussions among the reviewers.

The data extraction process involved compiling information on study characteristics, intervention types, policy frameworks, implementation challenges, and reported outcomes. The extracted data were synthesized thematically to identify recurring patterns, gaps in the literature, and emerging trends in AMR policy and practice. Thematic analysis allowed for the categorization of findings into key domains, including legislative approaches, antibiotic stewardship programs, surveillance systems, and public awareness campaigns.

The risk of bias in individual studies was assessed using the Critical Appraisal Skills Programme (CASP) checklist, which evaluates study reliability, validity, and applicability. Quality assessment ensured that findings were derived from robust methodologies and reliable data sources. The results of this systematic review are presented in accordance with PRISMA guidelines, with a flow diagram illustrating the study selection process.

The PRISMA flowchart shown in figure 1 visually represents the systematic process followed in study identification, screening, eligibility assessment, and final inclusion. It depicts the number of records identified through database searches, the number of duplicates removed, the number of studies excluded at each stage, and the final count of studies included in the review. This structured approach enhances transparency and reproducibility, ensuring that the review findings contribute meaningfully to the ongoing discourse on AMR policy and practice.



Fig 1: PRISMA Flow chart of the study methodology

2.1 Global policies and frameworks addressing AMR

Antimicrobial resistance (AMR) has increasingly been recognized as a prominent global public health threat, jeopardizing lives and compromising decades of medical progress. Notably, the World Health Organization (WHO) ranked AMR among the top ten global health challenges in 2019, drawing attention to its implications for health security and sustainable development goals, and necessitating comprehensive action to mitigate its impact (Sumpradit *et al*, 2021; Prestinaci *et al*, 2015).

Internationally, both developed and developing nations have responded to the AMR crisis by implementing strategies to curtail antibiotic resistance and promote sustainable antimicrobial practices. The WHO's Global Action Plan on Antimicrobial Resistance, initiated in 2015, represents a significant step in global efforts against AMR. This plan underscores a multisectoral approach that bridges human health, animal health, agriculture, and environmental management, endeavoring to ensure the efficacy of existing antimicrobials through enhanced awareness, surveillance, and infection control measures (Mupfunya *et al*, 2020; Willemsen *et al*, 2022). The plan identifies key strategic objectives: improving awareness; strengthening surveillance and research; reducing infection incidence; optimizing antimicrobial use; and fostering innovation in pharmaceuticals and diagnostics (Babarinde, *et al*, 2023, Willemsen *et al*, 2022).

In the United States, the National Action Plan for Combating Antibiotic-Resistant Bacteria provides a multifaceted strategy to address AMR issues within the country. This plan focuses on five core goals: slowing the spread of resistant bacteria, bolstering surveillance, expediting research and development for new antimicrobials, enhancing international collaboration, and promoting stewardship in antimicrobial use (Sumpradit *et al*, 2021; Prestinaci *et al*, 2015). U.S. health organizations, including the Centers for Disease Control and Prevention (CDC), work collaboratively to foster education, improve prescribing practices, and strengthen infection control in both healthcare settings and agricultural sectors (Rovirola *et al*, 2020).

Similarly, the European Union has adopted a comprehensive response to AMR through the European One Health Action Plan. This plan advocates for an integrated approach that recognizes the interconnectedness of human, animal, and environmental health, targeting improved surveillance, prudent antimicrobial use, and enhanced international cooperation (Prestinaci *et al*, 2015; Willemsen *et al*, 2022). Key initiatives include stringent regulations to limit antimicrobial use in agriculture and persistent investment in the development of novel antimicrobials and alternative therapies (Prestinaci *et al*, 2015; Chit & Grootendorst, 2018).

In contrast to their developed counterparts, many developing nations face unique obstacles in addressing AMR due to limited healthcare resources and insufficient regulatory frameworks. Despite these challenges, countries such as India, Brazil, and South Africa have started to implement national AMR action plans that emphasize stewardship, regulation, and public awareness (Sumpradit *et al*, 2021; Mupfunya *et al*, 2020; Mouiche *et al*, 2019). Initiatives in these countries have aimed to tighten regulations on antibiotic sales, enhance laboratory capacity for resistance monitoring, and initiate public campaigns to educate communities about appropriate antimicrobial use (Mouiche *et al*, 2019; Nkosi & Sibanda, 2021).

A comparative analysis of AMR strategies reveals significant disparities in implementation and effectiveness. Developed countries benefit from advanced surveillance systems, greater financial resources, and established healthcare infrastructures, contributing to more effective AMR responses ("Third joint inter-agency report on integrated analysis of consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the EU/EEA", 2021). Conversely, developing nations often struggle with public awareness, economic limitations, and weak regulatory enforcement, complicating their ability to combat AMR effectively (Mupfunya *et al*, 2020; Hesp *et al*, 2019). For example, a study highlighted the feasibility challenges that impede the application of national action plans in Cameroon, emphasizing the need for resource and capacity-building support (Amin *et al*, 2021). Diaz, Antonara & Barton, 2018, presented in figure 2 Factors leading to development of antimicrobial resistance and prevention measures at different levels.



Fig 2: Factors leading to development of antimicrobial resistance and prevention measures at different levels (Diaz, Antonara & Barton, 2018).

To adequately address the multifaceted challenges of AMR globally, future strategies must emphasize international collaboration and proactive engagement that transcends national boundaries. This entails strengthening global surveillance networks, enhancing equitable access to diagnostics and therapeutics, and promoting responsible use of antimicrobials across sectors (Mupfunya *et al*, 2020; Jackson *et al*, 2015). Additionally, investing in public education and professional training is crucial to cultivate a shared understanding and responsibility for combating AMR, driving coordinated action across all levels of society (Calvo-Villamañán *et al*, 2022).

In summary, the efforts to counter AMR through structured global frameworks like the WHO's Global Action Plan, the U.S. National Action Plan, and the European Union's One Health Action Plan highlight the critical need for a unified response to this pressing threat (Balogun, *et al*, 2023). While progress has been made, significant gaps remain, particularly in resource-limited settings, necessitating sustained commitment to enhance enforcement, improve healthcare capacities, and foster international partnerships for a comprehensive solution to AMR.

2.2 Antibiotic stewardship and regulatory measures

Antimicrobial resistance (AMR) poses an urgent global health threat, significantly exacerbated by the inappropriate use of antibiotics across various sectors—such as healthcare, communities, and agriculture (Green *et al*, 2023; Banda *et al*, 2020). A comprehensive understanding of AMR necessitates evaluating the diverse factors contributing to antibiotic misuse, including socioeconomic determinants and healthcare infrastructure inefficiencies (Green *et al*, 2023; Darwish *et al*, 2014). Effective interventions, such as antibiotic stewardship programs (ASPs) and regulatory measures, have emerged as critical strategies aimed at curbing antibiotic misuse and preserving the effectiveness of existing antimicrobials (Alkhuzaei *et al*, 2018; Dougnon *et al*, 2020). These efforts are grounded in global strategies accentuating the significance of responsible antibiotic use, robust regulatory frameworks, and public education initiatives to change behaviors associated with antibiotic consumption (Dougnon *et al*, 2020; Belachew *et al*, 2021). The key recommendations for continued support for antimicrobial resistance (AMR) research for clinical, research and policy stakeholders presented by Rodríguez-Baño, *et al*, 2021, is shown in figure 3.



Fig 3: Key recommendations for continued support for antimicrobial resistance (AMR) research for clinical, research and policy stakeholders (Rodríguez-Baño, *et al*, 2021).

Hospital-based ASPs have gained recognition as essential interventions to optimize antibiotic prescribing practices and mitigate the spread of resistant infections (Jayawardhana *et al*, 2023; Kabbani *et al*, 2019). These programs typically involve multidisciplinary teams—including infectious disease specialists, pharmacists, and clinical leadership—working collaboratively to develop guidelines for antibiotic selection, dosing, and administration (Moienzadeh *et al*, 2015; Barney *et al*, 2018). Key components of successful ASPs encompass strategies like prospective audit and feedback, wherein stewardship teams periodically evaluate antibiotic prescriptions, providing timely feedback to clinicians (Akande-Sholabi & Oyesiji, 2023). Additionally, formulary restrictions ensure that broad-spectrum antibiotics are prescribed only when clinically justified, consequently reducing exposure that fosters resistance development (Barney *et al*, 2018). Evidence shows that effective ASPs can lead to substantial reductions in antibiotic consumption, decreased rates of resistant infections such as Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile, alongside improved patient outcomes and cost savings (Lv *et al*, 2014; Hu *et al*, 2018).

Beyond hospital settings, community-based antibiotic stewardship programs are crucial for addressing antibiotic misuse in outpatient healthcare, encompassing clinics, pharmacies, and public health facilities (Nawafleh *et al*, 2017; Widayati *et al*, 2012). These programs fundamentally emphasize education for healthcare providers, standardized prescribing guidelines, and public health messaging that targets the understanding of AMR and appropriate antibiotic use among patients (Aleem *et al*, 2017; Rouusounides *et al*, 2011). The prevalence of inappropriate antibiotic prescriptions in outpatient settings is notable, often linked to respiratory and urinary tract infections (Darwish *et al*, 2014; Belachew *et al*, 2021). Therefore, interventions that promote public awareness about AMR, responsible antibiotic use, and alternatives to antibiotics are vital for shifting patient expectations and mitigating unnecessary prescriptions (Liu *et al*, 2021). Targeted educational initiatives for prescribers can further enhance adherence to clinical guidelines, ultimately contributing to reduced antibiotic misuse (Kabbani *et al*, 2019; Moienzadeh *et al*, 2015).

Regulatory frameworks governing antibiotic prescription and over-the-counter sales are imperative to enhancing antibiotic stewardship (Belachew *et al*, 2021; Dougnon *et al*, 2020). Many countries have instituted regulations mandating prescription-only access to antibiotics, which significantly diminishes self-medication and misuse (Darwish *et al*, 2014). Various successful models globally include stringent prescription requirements and controlled pharmacy practices, effectively limiting antibiotic availability and promoting rational use (Alkhuzaei *et al*, 2018). However, challenges persist, especially in developing countries, where resource constraints hinder effective regulatory implementation (Green *et al*, 2023; Banda *et al*, 2020). Achieving long-term success in regulating antibiotic sales requires international collaboration and strengthened local capacities (Peng *et al*, 2018; Akande-Sholabi & Oyesiji, 2023). Bhatia, 2018, presented Linkages between objectives of antimicrobial resistance (AMR) action plan and key elements of Universal Health Coverage (UHC) shown in figure 4.



Fig 4: Linkages between objectives of antimicrobial resistance (AMR) action plan and key elements of Universal Health Coverage (UHC) (Bhatia, 2018).

Addressing antibiotic misuse in agriculture is also critical in the global strategy against AMR. The indiscriminate use of antibiotics in livestock for growth promotion and disease prevention creates environmental reservoirs of resistant pathogens (Rouusounides *et al*, 2011; Jamiu *et al*, 2020). Regulations to curb such practices include bans on antibiotic use as growth promoters and requirements for veterinary oversight in antibiotic administration (Hu *et al*, 2018; Jayawardhana *et al*, 2023). Moreover, guidelines promoting improved animal husbandry, vaccination programs, and alternative health interventions are essential for the responsible use of antibiotics in agriculture (Lv *et al*, 2014; Dougnon *et al*, 2020).

Public awareness campaigns and behavioral interventions are necessary complements to these strategies, as they raise understanding of antibiotic misuse and promote responsible behaviors among both healthcare professionals and the community at large (Thuy *et al*, 2021; Peng *et al*, 2018). Successful campaigns, such as the UK's "Keep Antibiotics Working" and WHO's annual "World Antibiotic Awareness Week," exemplify the potential for comprehensive awareness initiatives to change public attitudes about antibiotics and foster compliance with stewardship efforts (Widayati *et al*, 2012). By employing diverse communication strategies, these campaigns effectively disseminate information about AMR and encourage responsible antibiotic use, thereby paving the way for sustainable behavioral change (Nováková *et al*, 2011; Hu *et al*, 2018).

In summary, multifaceted approaches are essential for effectively addressing AMR through antibiotic stewardship programs and regulatory frameworks. The cooperative efforts of hospital and community-based programs, stringent prescription regulations, responsible agricultural practices, and robust public awareness initiatives form a synergistic framework crucial for combating antibiotic misuse and preserving antimicrobial efficacy (Balogun, *et al*, 2023). Nevertheless, ongoing challenges, especially in developing nations, call for targeted efforts in capacity-building, education, and international collaboration to achieve lasting improvements in antibiotic stewardship.

2.3 Technological and scientific innovations for AMR control

Antimicrobial resistance (AMR) represents a critical global health threat as it undermines the efficacy of antibiotics, complicating the treatment of various infectious diseases. The increasing prevalence of multidrug-resistant pathogens necessitates innovative strategies to combat AMR. Emerging technologies—such as artificial intelligence (AI), big data analytics, precision medicine, alternative therapeutics, rapid diagnostics, and blockchain—are transforming public health strategies used to control and prevent AMR (Bidemi, *et al*, 2021; Dirlikov, 2021).

AI and big data analytics have emerged as powerful tools for enhancing AMR surveillance. By leveraging extensive datasets from electronic health records, laboratory diagnostics, and genomic sequencing, AI algorithms can predict resistance patterns and optimize antibiotic prescribing. These technologies facilitate real-time data analysis that supports effective clinical decision-making (Anahtar *et al*, 2021; Sakagianni *et al*, 2023). For instance, AI-driven surveillance systems can map the emergence and spread of resistant pathogens, providing critical information that aids healthcare providers and public health authorities in guiding interventions (Anahtar *et al*, 2021).

Moreover, precision medicine is revolutionizing treatment approaches, empowering clinicians to personalize antimicrobial therapies based on individual genetic profiles and pathogen-specific attributes. Genetic profiling facilitates rapid identification of specific pathogens and their resistance mechanisms, enabling targeted treatment plans that minimize broad-spectrum antibiotic use (Alqahtani *et al*, 2022, Dirlikov, *et al*, 2021). This shift towards narrow-spectrum antibiotics minimizes collateral damage to beneficial microbiota, reducing selection pressure for resistance (Alqahtani *et al*, 2022). The implementation of personalized, targeted treatments not only enhances clinical outcomes but also addresses AMR effectively (Alqahtani *et al*, 2022).

In addition to AI and precision medicine, alternative therapeutics are gaining traction as viable strategies for AMR control. Bacteriophage therapy, which utilizes bacteriophages to specifically target bacterial pathogens, has shown potential in treating infections caused by multidrug-resistant bacteria (Alqahtani *et al*, 2022; Efobi, *et al*, 2023). Recent advances in genetic engineering and formulation technologies have revitalized interest in this approach, showcasing its effectiveness against resistant strains such as carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus (MRSA) (Alqahtani *et al*, 2022). Furthermore, antimicrobial peptides (AMPs) and probiotics represent promising alternatives that exhibit broad-spectrum efficacy against resistant bacteria while minimizing the likelihood of resistance development (Alqahtani *et al*, 2022).

Rapid diagnostic technologies are crucial for optimizing antibiotic use and improving clinical decision-making. Point-of-care diagnostics enable healthcare providers to swiftly identify pathogens and their susceptibility profiles, significantly reducing the time to initiate appropriate therapy (Alqahtani *et al*, 2022). Cutting-edge innovations, such as CRISPR-based diagnostics, enhance detection accuracy, facilitating timely interventions that are vital for effective AMR control (Alqahtani *et al*, 2022). These rapid diagnostic advancements empower clinicians to tailor treatment approaches swiftly, thereby reducing inappropriate antibiotic usage and improving patient outcomes (Alqahtani *et al*, 2022; Elujide, *et al*, 2021).

Blockchain technology offers significant potential for addressing issues related to the integrity of antibiotic supply chains. By providing a transparent, immutable ledger for tracking antibiotic products, blockchain can combat the proliferation of counterfeit medications—an issue that exacerbates AMR, especially in resource-limited settings (Alqahtani *et al*, 2022). Implementing blockchain systems can improve antibiotic quality assurance, reduce misuse, and enhance regulatory oversight, contributing to the global efforts in combating AMR (Elujide, *et al*, 2021).

In conclusion, the confluence of technological and scientific innovations is reshaping global strategies to mitigate the threat of antimicrobial resistance. AI and big data analytics enhance surveillance and clinical decision-making, while precision medicine personalizes treatment approaches to reduce broad-spectrum antibiotic reliance. Alternative therapies, rapid diagnostics, and blockchain technology contribute additional layers of defense against AMR (Fagbule, *et al*, 2023; Jahun, *et al*, 2021). However, realizing these innovations' full potential requires strategic investments, regulatory support, interdisciplinary collaboration, and public awareness initiatives. Overall, these emerging technologies represent a comprehensive approach to promoting effective AMR management and protecting public health.

2.4 Challenges and barriers to AMR policy implementation

Antimicrobial resistance (AMR) poses one of the most significant global public health challenges, with the potential to reverse many of the medical advancements made over the last few decades. The complexity of AMR is compounded by persistent challenges that hinder the effective implementation of both national and international policies aimed at combating this crisis (Jahun, *et al*, 2021; Obi, *et al*, 2023). A broad consensus emerges from the literature indicating that fragmented global coordination represents a primary obstacle in addressing AMR effectively. Although the World Health Organization (WHO) has established a Global Action Plan, there is considerable variability in how different nations implement and enforce these guidelines due to differences in political commitment, healthcare infrastructure, and resource availability (Wernli *et al*, 2017; Ogyu *et al*, 2020). This fragmentation allows AMR to flourish across borders, as regions with weaker regulatory frameworks become breeding grounds for resistant pathogens, thereby heightening global health risks (Sumpradit *et al*, 2021; Anderson *et al*, 2019; Obi, *et al*, 2023).

Economic constraints further exacerbate the challenges associated with AMR policy implementation. The pharmaceutical industry's hesitance to invest in antibiotic development stems from the low economic returns associated with these drugs, particularly in comparison to treatments for chronic diseases (Ogunboye, *et al*, 2023). Research indicates that this lack of investment results in a frail antibiotic development pipeline, exacerbated by poor public-sector funding for research and infrastructure in low- and middle-income countries (LMICs) (Jensen, 2020; Dadgostar, 2019; Ogundairo, *et al*, 2023). The implications of inadequate investment in AMR research and development (R&D) are significant, fostering an environment where novel and effective antimicrobials are rarely introduced into the market

(Ogundairo, *et al*, 2023; Overton *et al*, 2021). Addressing this funding gap necessitates innovative financing solutions and collaborative approaches that engage both private and public stakeholders in AMR-related R&D (Ogungbenle & Omowole, 2012; Sharma *et al*, 2020).

In addition to economic challenges, ethical considerations play a critical role in societal acceptance and effective implementation of AMR policies. Proposed interventions, such as restrictions on antibiotic access or regulations against agricultural antibiotic use, may evoke public resistance, particularly in contexts where access to medications is already limited (Adepoju, *et al*, 2023: Okolie, *et al*, 2021). This resistance is often fueled by misconceptions about AMR that persist in communities, leading to skepticism toward new therapeutic approaches or interventions (Chan *et al*, 2022; Davis *et al*, 2020). Studies highlight the importance of engaging the public through transparent dialogue and education initiatives that elucidate the rationale behind AMR policies and their long-term benefits for public health (Poomchaichote *et al*, 2023; Onah & Umar, 2023). Enhancing stakeholder engagement can alleviate some societal tensions and encourage more robust support for AMR strategies.

Moreover, significant gaps in education and public awareness regarding appropriate antibiotic use continue to undermine AMR policy effectiveness. Research has shown that widespread misconceptions persist in many populations, particularly in resource-limited settings, where the understanding of antibiotic misuse and its consequences remains alarmingly low (Chea *et al*, 2022; Kariuki *et al*, 2022). Initiatives to bolster public awareness and education around AMR must be culturally tailored and sustained to ensure broad outreach and community engagement (Catalán-Matamoros *et al*, 2019; Odionu & Ibeh, 2023). Furthermore, educational programs for healthcare providers themselves need to be prioritized and expanded to cultivate effective stewardship practices (Chanvatik *et al*, 2019; Kumar *et al*, 2013; Paul, *et al*, 2021). Overall, promoting a greater understanding of AMR through comprehensive education campaigns is vital for fostering responsible antibiotic use and shaping public attitudes toward the necessity of stringent AMR policies.

Lastly, the challenges posed by insufficient healthcare infrastructure in many developing countries limit the implementation of effective AMR policies. Issues such as inadequate diagnostic capabilities and weak regulatory enforcement mechanisms undermine the surveillance and treatment of resistant infections (McParland *et al*, 2018; Uwumiro, *et al*, 2023). Strengthening healthcare infrastructures necessitates strategic global investments and collaborations aimed at improving diagnostic capabilities and promoting responsible antibiotic use (Willemsen *et al*, 2022). The One Health approach, which integrates human, animal, and environmental health, is increasingly recognized as a necessary framework for addressing the interrelations underlying AMR and supporting efforts toward sustainable solutions globally (Sumpradit *et al*, 2021).

In summary, the effective implementation of AMR policies faces multifaceted barriers, including fragmented global coordination, economic disincentives, ethical considerations, public resistance, gaps in education, and insufficient healthcare infrastructure. Overcoming these challenges requires comprehensive strategies that enhance international cooperation, promote public education, and inject necessary resources into AMR initiatives. Through concerted efforts among policymakers, health organizations, and communities, it is possible to mitigate the threat posed by AMR and safeguard public health for future generations.

2.5 Actionable strategies for combating AMR

Antimicrobial resistance (AMR) is increasingly recognized as a significant global health crisis that threatens the achievements of modern medicine, public health systems, and economic stability. The World Health Organization (WHO) characterizes AMR as a cross-cutting issue that has considerable implications for human, animal, and environmental health, which calls for systemic and comprehensive policy responses across various sectors (Fuller *et al*, 2022; Hay *et al*, 2018). These responses must address the complexity of AMR, necessitating coordinated international efforts, including frameworks like the WHO's Global Action Plan on AMR, designed to strengthen global collaborative efforts (Keck *et al*, 2023).

A fundamental aspect of combating AMR is the enhancement of international collaboration among nations, healthcare providers, and stakeholders across sectors. AMR knows no borders, underscoring the necessity for harmonized policies and standardized guidelines. International surveillance frameworks, such as the Global Antimicrobial Resistance and Usage Surveillance System (GLASS), exemplify initiatives aimed at fostering uniform reporting and data collection, which are critical for effective policy development and intervention strategies (Ashley *et al*, 2018). However, the successful realization of these frameworks' hinges on robust governance structures that ensure coordinated responses and sustained financial commitments to assist less economically advantaged nations in developing necessary human and infrastructural capacities (Cong *et al*, 2023).

Furthermore, promoting responsible antimicrobial usage and encouraging innovation in drug development are essential strategies to alleviate the challenges posed by stagnant antibiotic pipelines. Financial complexities, such as high development costs and limited profitability, discourage pharmaceutical companies from investing in antimicrobial research and development (R&D) (Oberin *et al*, 2022). Incentives, such as public-private partnerships and subsidies for research and early-stage development of new antimicrobials, are recommended to stimulate investment in this critical area (Schnall *et al*, 2019). This reflects a pressing need to create a robust ecosystem that not only supports existing antimicrobials through stewardship but also fosters the development of novel therapies capable of counteracting resistant pathogens.

Moreover, implementing and strengthening infection prevention and control (IPC) measures across healthcare systems can significantly contribute to reducing the pressure for antibiotic use and consequently the development of AMR (Otto *et al*, 2022). Improving hand hygiene, environmental sanitation, and adherence to clinical guidelines is vital within healthcare facilities and extends to community healthcare settings and agriculture (Lahra *et al*, 2018). Initiatives aimed at changing behavior among healthcare providers, agricultural practitioners, and the general public through education are crucial for reinforcing these IPC strategies (Cassini *et al*, 2019).

Expanding and enhancing global surveillance systems is also integral in managing AMR. The current fragmented surveillance systems often result in insufficient data to effectively inform public health policy (Turner *et al*, 2019). Comprehensive surveillance must encompass human, animal, and environmental dimensions, thereby allowing for a holistic understanding of resistance dynamics. Leveraging modern technologies such as artificial intelligence and big data analytics can improve the efficiency of data collection and sharing (Zingg *et al*, 2019). Establishing open-access platforms that unify AMR data across sectors would empower stakeholders to make informed decisions based on timely and reliable data (Walia *et al*, 2019).

Finally, adopting a One Health approach to AMR policy highlights the interconnectedness of human, animal, and environmental health, advocating for a multidisciplinary strategy that fosters collaborative efforts among various stakeholders. This approach is essential for developing coordinated responses to AMR across all relevant sectors (Camara *et al*, 2023). Initiatives to regulate antibiotic use in agriculture and veterinary medicine are critical, as the overuse of these agents in animal husbandry contributes significantly to the development of resistant strains affecting human health (Nellums *et al*, 2018).

In conclusion, effectively addressing the multifaceted challenge of antimicrobial resistance entails comprehensive strategies, including strengthening international collaboration, fostering drug development, enhancing infection control measures, and establishing robust and integrated surveillance systems. The interdependencies of these strategies necessitate a collective commitment to empowering healthcare systems globally, ensuring equitable access to antimicrobials and fostering sustainable practices that will mitigate the threat of AMR for future generations.

3. Conclusion and Recommendations

Antimicrobial resistance (AMR) remains one of the most significant global public health threats of our time, demanding urgent, coordinated, and innovative action across sectors and international boundaries. This systematic review has thoroughly evaluated innovative global policies, practices, and technological advancements aimed at reducing AMR, highlighting several critical areas that require targeted attention, investment, and global cooperation. Central to this analysis are key findings demonstrating the importance of comprehensive antibiotic stewardship programs, robust regulatory frameworks, advanced technological and scientific innovations, integrated One Health approaches, and strengthened global surveillance infrastructures.

The review underscores the necessity and effectiveness of antibiotic stewardship programs in hospitals and community settings as foundational strategies for AMR mitigation. Stewardship initiatives have consistently proven effective in curbing inappropriate antibiotic use, decreasing healthcare-associated infections, reducing rates of resistant pathogens, and improving patient outcomes. However, successful stewardship implementation varies considerably between developed and developing nations due to disparities in resources, infrastructure, and regulatory enforcement capacities. Addressing these disparities requires strengthened international collaboration, increased resource allocation, and enhanced technical assistance to ensure equitable global implementation of effective stewardship interventions.

Global policies such as the World Health Organization’s Global Action Plan on AMR, the United States’ National Action Plan for Combating Antibiotic-Resistant Bacteria, and the European Union’s One Health Action Plan have provided crucial frameworks for coordinated international responses. Nonetheless, fragmented global coordination and inconsistent policy enforcement remain significant barriers, exacerbating vulnerabilities within weaker healthcare systems and agricultural practices. Harmonizing policies across nations, standardizing surveillance protocols, and fostering unified international regulatory frameworks are imperative for overcoming these challenges. Improved global governance, transparent data-sharing mechanisms, and sustained political commitment are necessary to bridge the implementation gap between developed and resource-limited countries.

Technological and scientific innovations, including artificial intelligence (AI), precision medicine, alternative therapeutics, rapid diagnostic technologies, and blockchain-enabled supply chains, have emerged as powerful tools in the fight against AMR. AI-driven predictive analytics significantly enhance surveillance by predicting resistance patterns and optimizing antibiotic prescribing. Precision medicine approaches, supported by genetic profiling and rapid diagnostics, facilitate targeted antimicrobial therapies, substantially reducing reliance on broad-spectrum antibiotics and mitigating resistance development. Additionally, alternative therapies such as bacteriophage treatments, antimicrobial peptides, and probiotics offer promising avenues for reducing dependence on conventional antibiotics, diversifying therapeutic strategies against resistant infections. Blockchain technologies strengthen antibiotic supply chain transparency, reduce counterfeit medications, and improve global antibiotic quality assurance. Expanding investment and research in these technological innovations represents a critical pathway toward sustainable, effective AMR control.

Despite these promising strategies, critical barriers impede effective implementation, including economic and funding limitations, ethical concerns, public resistance, and educational deficiencies. Economic disincentives significantly hinder antibiotic development and innovation, requiring strategic incentives and public-private partnerships to reinvigorate pharmaceutical research. Ethical challenges associated with restrictive antibiotic policies necessitate transparent stakeholder engagement, equitable access provisions, and careful balancing of stewardship enforcement with healthcare accessibility. Furthermore, significant educational gaps persist among healthcare providers, agricultural stakeholders, and the public, necessitating culturally tailored awareness campaigns, continuous professional training, and robust community engagement to foster sustainable behavioral changes regarding antibiotic usage.

Based on the findings of this systematic review, several actionable policy recommendations emerge for governments and global health organizations. Governments should prioritize AMR within national agendas, allocating sufficient financial and human resources toward strengthening healthcare infrastructures, regulatory capacities, diagnostic capabilities, and stewardship training programs. Harmonized international policies and collaborative frameworks must be fostered, supported by unified regulatory standards and mutual recognition of stewardship protocols to facilitate coordinated global responses. Global health organizations, particularly WHO, should continue to lead international coordination efforts, advocating for sustainable funding, equitable resource distribution, and capacity-building assistance targeting resource-limited countries.

Incentivizing antibiotic research and development should become a global priority, with governments implementing innovative economic models, including market-entry rewards, regulatory incentives, and collaborative funding mechanisms to stimulate private-sector antibiotic innovation. Strategic international collaboration, leveraging public-private partnerships, should drive investments in novel antibiotics, alternative therapeutics, rapid diagnostic technologies, and precision medicine tools, significantly advancing AMR mitigation efforts. Moreover, policymakers should enforce robust regulatory measures, including stringent restrictions on antibiotic sales, prescriptions, and agricultural antibiotic use, supported by comprehensive monitoring and enforcement mechanisms.

Future directions in AMR research and technological advancements must emphasize further integration of AI-driven surveillance systems, precision medicine approaches, rapid diagnostic tools, and alternative therapeutic developments. Research should focus on refining predictive algorithms, enhancing diagnostic sensitivity and specificity, developing new narrow-spectrum antibiotics, and expanding clinical trials for bacteriophage therapies and antimicrobial peptides. Additional emphasis must be placed on integrating blockchain technologies globally to strengthen antibiotic supply chain integrity and transparency.

Advancing interdisciplinary One Health research remains essential, recognizing the interconnected nature of human, animal, and environmental health sectors. Research efforts should intensify investigations into environmental reservoirs of resistance, transmission dynamics across ecosystems, and effective interventions within agricultural and veterinary practices. Addressing environmental AMR through improved waste management, pharmaceutical residue control, and ecological monitoring must become integral components of future AMR strategies.

Educational research must focus on identifying effective public awareness methodologies, culturally sensitive communication strategies, and behavioral interventions capable of sustainably influencing antibiotic prescribing practices and public antibiotic usage behaviors globally. Leveraging digital media, social platforms, and targeted educational campaigns offers significant opportunities to close knowledge gaps, reduce misconceptions, and foster collective responsibility for antibiotic stewardship.

In conclusion, effectively combating antimicrobial resistance requires sustained international commitment, harmonized global policies, targeted financial investments, innovative technological solutions, and comprehensive educational strategies. Addressing AMR necessitates strengthened international collaboration, strategic incentives for antibiotic innovation, expanded global surveillance networks, enhanced infection prevention protocols, and integrated One Health approaches. By systematically implementing these recommendations, governments, global health organizations, healthcare systems, and communities can collectively advance global AMR control, protecting public health and safeguarding the efficacy of antibiotics for current and future generations.

4. Reference

1. Adepoju PA, Akinade AO, Ige AB, Afolabi AI. A systematic review of cybersecurity issues in healthcare IT: Threats and solutions. Iconic Research and Engineering Journals. 2023;7(10).
2. Ahmed N, Haseeb A, Hassali A, Khan A. Antimicrobial stewardship interventions: narrative review. Journal of Pharmaceutical Research International. 2021;33:62–71. https://doi.org/10.9734/jpri/2021/v33i23b31422
3. Akande-Sholabi W, Oyesiji E. Antimicrobial stewardship: knowledge, perceptions, and factors associated with antibiotics misuse among consumers visiting the community pharmacies in a Nigeria southwestern state. Journal of Pharmaceutical Policy and Practice. 2023;16(1). https://doi.org/10.1186/s40545-023-00629-x
4. Al Zoubi MAM, Amafah J, Temedie-Asogwa T, Atta JA. International Journal of Multidisciplinary Comprehensive Research. 2022.
5. Aleem M, Rahman M, Ishfaq M, Mehmood K, Ahmed S. Determinants of antibiotics misuse by the parents in children: a survey from northern region of Saudi Arabia. Bangladesh Journal of Child Health. 2017;40(2):64–71. https://doi.org/10.3329/bjch.v40i2.31560
6. Alkhuzaei A, Salama R, Eljak I, Chehab M, Selim N. Perceptions and practice of physicians and pharmacists regarding antibiotic misuse at primary health centres in Qatar: a cross-sectional study. Journal of Taibah University Medical Sciences. 2018;13(1):77–82. https://doi.org/10.1016/j.jtumed.2017.09.001
7. Alqahtani F, Almustafa H, Alshehri R, Alanazi S, Khalifa A. Combating antibiotic resistance in bacteria: the development of novel therapeutic strategies. Journal of Pure and Applied Microbiology. 2022;16(4):2201–2224. https://doi.org/10.22207/jpam.16.4.01
8. Amafah J, Temedie-Asogwa T, Atta JA, Al Zoubi MAM. The impacts of treatment summaries on patient-centered communication and quality of care for cancer survivors. Unpublished. 2023.
9. Amin E, Omeichu A, Shu D, Ekome S, Njumkeng C, Sande M. Control of antimicrobial resistance in Cameroon: feasibility of implementing the national action plan. Tropical Medicine & International Health. 2021;26(10):1231–1239. https://doi.org/10.1111/tmi.13649
10. Anahtar M, Yang J, Kanjilal S. Applications of machine learning to the problem of antimicrobial resistance: an emerging model for translational research. Journal of Clinical Microbiology. 2021;59(7). https://doi.org/10.1128/jcm.01260-20
11. Anderson M, Schulze K, Cassini A, Plachouras D, Mossialos E. A governance framework for development and assessment of national action plans on antimicrobial resistance. The Lancet Infectious Diseases. 2019;19(11):e371–e384. https://doi.org/10.1016/s1473-3099(19)30415-3
12. Ashley E, Recht J, Chua A, Dance D, Dhorda M, Thomas N, et al. An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000. Journal of Antimicrobial Chemotherapy. 2018;73(7):1737–1749. https://doi.org/10.1093/jac/dky026
13. Atif M, Tufail S. Knowledge and perception of doctors regarding antibiotic stewardship in a tertiary care hospital of southern Punjab. International Journal of Endorsing Health Science Research. 2022;10(2):179–187. https://doi.org/10.29052/ijehsr.v10.i2.2022.179-187

14. Atta JA, Al Zoubi MAM, Temedie-Asogwa T, Amafah J. Comparing the cost-effectiveness of pharmaceutical vs. non-pharmaceutical interventions for diabetes management. Unpublished. 2021.
15. European Food Safety Authority (EFSA), European Medicines Agency (EMA). Third joint inter-agency report on integrated analysis of consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the EU/EEA: JIACRA III 2016-2018. EFSA Journal. 2021;19(6):e06712.
16. Ayo-Farai O, Ogundairo O, Maduka CP, Okongwu CC, Babarinde AO, Sodamade OT. Telemedicine in health care: a review of progress and challenges in Africa. Matrix Science Pharma. 2023;7(4):124–132.
17. Babarinde AO, Ayo-Farai O, Maduka CP, Okongwu CC, Sodamade O. Data analytics in public health, a USA perspective: a review. World Journal of Advanced Research and Reviews. 2023;20(3):211–224.
18. Babarinde AO, Ayo-Farai O, Maduka CP, Okongwu CC, Ogundairo O, Sodamade O. Review of AI applications in healthcare: comparative insights from the USA and Africa. International Medical Science Research Journal. 2023;3(3):92–107.
19. Babarinde AO, Balogun MR, Odugbemi TO. Knowledge, attitude, and use of mobile phones to acquire health-related information among students of Yaba College of Technology, Lagos. Unpublished. 2018.
20. Balogun OD, Ayo-Farai O, Ogundairo O, Maduka CP, Okongwu CC, Babarinde AO, Sodamade OT. Innovations in drug delivery systems: a review of the pharmacist's role in enhancing efficacy and patient compliance. Unpublished. 2023.
21. Balogun OD, Ayo-Farai O, Ogundairo O, Maduka CP, Okongwu CC, Babarinde AO, Sodamade OT. Integrating AI into health informatics for enhanced public health in Africa: a comprehensive review. International Medical Science Research Journal. 2023;3(3):127–144.
22. Banda M, Neene V, Mudenda S. Community pharmacists' role as antibiotic stewards in the fight against coronavirus disease 2019. World Journal of Advanced Research and Reviews. 2020;8(1):001–005. https://doi.org/10.30574/wjarr.2020.8.1.0312
23. Barney G, Felsen C, Dumyati G. One-day point prevalence as a method for estimating antibiotic use in nursing homes. Infection Control and Hospital Epidemiology. 2018;40(2):221–223. https://doi.org/10.1017/ice.2018.309
24. Belachew S, Hall L, Erku D, Selvey L. No prescription? No problem: drivers of non-prescribed sale of antibiotics among community drug retail outlets in low- and middle-income countries: a systematic review of qualitative studies. BMC Public Health. 2021;21(1). https://doi.org/10.1186/s12889-021-11163-3
25. Bhatia R. Universal health coverage framework to combat antimicrobial resistance. Indian Journal of Medical Research. 2018;147(3):228–232.
26. Bidemi AI, Oyindamola FO, Odum I, Stanley OE, Atta JA, Olatomide AM, et al. Challenges Facing Menstruating Adolescents: A Reproductive Health Approach. Journal of Adolescent Health. 2021;68(5):1-10.
27. Calvo-Villamañán A, Millán Á, Carrilero L. Tackling AMR from a multidisciplinary perspective: A primer from education and psychology. International Microbiology. 2022;26(1):1-9. https://doi.org/10.1007/s10123-022-00278-1
28. Camara N, Moremi N, Mghamba J, Eliakimu E, Shumba E, Ondoa P, et al. Surveillance of antimicrobial resistance in human health in Tanzania: 2016–2021. African Journal of Laboratory Medicine. 2023;12(1). https://doi.org/10.4102/ajlm.v12i1.2053
29. Cassini A, Högberg L, Plachouras D, Quattrocchi A, Hoxha A, Simonsen G, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. The Lancet Infectious Diseases. 2019;19(1):56-66. https://doi.org/10.1016/S1473-3099(18)30605-4
30. Catalán-Matamoros D, Pariente A, Elías C. What we know about media communication on antibiotics and antimicrobial resistance: A systematic review of the scientific literature. Patient Education and Counseling. 2019;102(8):1427-1438. https://doi.org/10.1016/j.pec.2019.03.020
31. Chan O, Lam W, Fukuda K, Tun H, Ohmagari N, Littmann J, et al. Antimicrobial resistance policy protagonists and processes—a qualitative study of policy advocacy and implementation. Antibiotics. 2022;11(10):1434. https://doi.org/10.3390/antibiotics11101434
32. Chanvatik S, Kosiyaporn H, Lekagul A, Kaewkhankhaeng W, Vongmongkol V, Thunyahan A, et al. Knowledge and use of antibiotics in Thailand: A 2017 national household survey. PLOS ONE. 2019;14(8):e0220990. https://doi.org/10.1371/journal.pone.0220990
33. Chea B, Kong S, Thim S, Ban N, Seng S, Fernandez-Colorado C, et al. Knowledge, attitudes, and practices of antimicrobial use and resistance among livestock producers in Cambodia. Open Journal of Animal Sciences. 2022;12(3):454-466. https://doi.org/10.4236/ojas.2022.123034
34. Chit A, Grootendorst P. Policy to encourage the development of antimicrobials. International Journal of Health Governance. 2018;23(2):101-110. https://doi.org/10.1108/IJHG-12-2017-0062
35. Cong P, Assefa Y, Batikawai S, Reid S. Strengthening antimicrobial resistance surveillance systems: A scoping review. BMC Infectious Diseases. 2023;23(1). https://doi.org/10.1186/s12879-023-08585-2
36. Dadgostar P. Antimicrobial resistance: Implications and costs. Infection and Drug Resistance. 2019;12:3903-3910. https://doi.org/10.2147/IDR.S234610
37. Darwish D, Abdelmalek S, Dayyih W, Hamadi S. Awareness of antibiotic use and antimicrobial resistance in the Iraqi community in Jordan. The Journal of Infection in Developing Countries. 2014;8(5):616-623. https://doi.org/10.3855/jidc.4086
38. Davis M, Lohm D, Whittaker A, Flowers P. 'Willy nilly' doctors, bad patients, and resistant bodies in general public explanations of antimicrobial resistance. Sociology of Health & Illness. 2020;42(6):1394-1408. https://doi.org/10.1111/1467-9566.13111
39. Diaz A, Antonara S, Barton T. Prevention strategies to combat antimicrobial resistance in children in resource-limited settings. Current Tropical Medicine Reports.

2018;5:5-15.

40. Dirlikov E. Rapid scale-up of an antiretroviral therapy program before and during the COVID-19 pandemic—Nine states, Nigeria, March 31, 2019–September 30, 2020. MMWR. Morbidity and Mortality Weekly Report. 2021;70.
41. Dirlikov E, Jahun I, Odafe SF, Obinna O, Onyenuobi C, Ifunanya M, et al. Rapid scale-up of an antiretroviral therapy program before and during the COVID-19 pandemic—Nine states, Nigeria, March 31, 2019–September 30, 2020. MMWR. Morbidity and Mortality Weekly Report. 2021;70.
42. Dougnon V, Chabi Y, Koudokpon H, Agbankpé A, Sefounon R, Alle D, et al. Prescription of antibiotics as a source of emerging antibiotic resistance: Knowledge, attitudes, and practices of medical staff in the Dassa-Glazoué and Savalou-Bantè's health zones (Benin, West Africa). International Journal of One Health. 2020;6(1):34-40. https://doi.org/10.14202/IJOH.2020.34-40
43. Efobi CC, Nri-ezedi CA, Madu CS, Obi E, Ikediashi CC, Ejiofor O. A retrospective study on gender-related differences in clinical events of sickle cell disease: A single centre experience. Tropical Journal of Medical Research. 2023;22(1):137-144.
44. Elujide I, Fashoto SG, Fashoto B, Mbunge E, Folorunso SO, Olamijuwon JO. Informatics in Medicine Unlocked.
45. Elujide I, Fashoto SG, Fashoto B, Mbunge E, Folorunso SO, Olamijuwon JO. Application of deep and machine learning techniques for multi-label classification performance on psychotic disorder diseases. Informatics in Medicine Unlocked. 2021;23:100545.
46. Fagbule OF, Amafah JO, Sarumi AT, Ibitoye OO, Jakpor PE, Oluwafemi AM. Sugar-sweetened beverage tax: A crucial component of a multisectoral approach to combating non-communicable diseases in Nigeria. Nigerian Journal of Medicine. 2023;32(5):461-466.
47. Fuller W, Aboderin A, Yahaya A, Adeyemo A, Gahimbare L, Kapona O, et al. Gaps in the implementation of national core elements for sustainable antimicrobial use in the WHO-African region. Frontiers in Antibiotics. 2022;1. https://doi.org/10.3389/frabi.2022.1047565
48. Green D, Keenan K, Fredricks K, Huque S, Mushi M, Kansiime C, et al. The role of multidimensional poverty in antibiotic misuse: A mixed-methods study of self-medication and non-adherence in Kenya, Tanzania, and Uganda. The Lancet Global Health. 2023;11(1):e59-e68. https://doi.org/10.1016/S2214-109X(22)00423-5
49. Hay S, Rao P, Dolecek C, Day N, Stergachis A, Lopez A, et al. Measuring and mapping the global burden of antimicrobial resistance. BMC Medicine. 2018;16(1). https://doi.org/10.1186/s12916-018-1073-z
50. Hesp A, Veldman K, Goot J, Mevius D, Schaik G. Monitoring antimicrobial resistance trends in commensal Escherichia coli from livestock, The Netherlands, 1998 to 2016. Eurosurveillance. 2019;24(25). https://doi.org/10.2807/1560-7917.ES.2019.24.25.1800438.
51. Hu Y, Wang X, Tucker J, Little P, Moore M, Fukuda K, et al. Knowledge, attitude, and practice with respect to antibiotic use among Chinese medical students: a multicentre cross-sectional study. International Journal of Environmental Research and Public Health. 2018;15(6):1165. https://doi.org/10.3390/ijerph15061165
52. Isolates from foreign-born population in the European gonococcal antimicrobial surveillance programme. Sexually Transmitted Infections. 2020;96(3):204-210. https://doi.org/10.1136/sextrans-2018-053912
53. Jackson C, Davis J, Frye J, Barrett J, Hiott L. Diversity of plasmids and antimicrobial resistance genes in multidrug-resistant Escherichia coli isolated from healthy companion animals. Zoonoses and Public Health. 2015;62(6):479-488. https://doi.org/10.1111/zph.12178
54. Jahun I, Dirlikov E, Odafe S, Yakubu A, Boyd AT, Bachanas P, et al. Ensuring optimal community HIV testing services in Nigeria using an enhanced community case-finding package (ECCP), October 2019–March 2020: acceleration to HIV epidemic control. HIV/AIDS-Research and Palliative Care. 2021;13:839-850.
55. Jahun I, Said I, El-Imam I, Ehoche A, Dalhatu I, Yakubu A, et al. Optimizing community linkage to care and antiretroviral therapy initiation: Lessons from the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) and their adaptation in Nigeria ART Surge. PLoS One. 2021;16(9):e0257476. https://doi.org/10.1371/journal.pone.0257476
56. Jamiu M, Fatima A, Onozare A. Pattern of self-medication with prescription medicines among residents of Ilorin in north central Nigeria. RADS Journal of Pharmacy and Pharmaceutical Sciences. 2020;7(4):191-198. https://doi.org/10.37962/jpps.v7i4.353
57. Jayawardhana Y, Premaratne A, Kalpani S, Jayasundara S, Jayawardhane G, Jayawarna C, et al. Investigating the drivers for antibiotic use and misuse amongst medical undergraduates: perspectives from a Sri Lankan medical school. PLOS Global Public Health. 2023;3(3):e0001740. https://doi.org/10.1371/journal.pgph.0001740
58. Jensen C. While we are waiting for the superbug: constitutional asymmetry and EU governmental policies to combat antimicrobial resistance. JCMS Journal of Common Market Studies. 2020;58(6):1361-1376. https://doi.org/10.1111/jcms.13041
59. Kabbani S, Palms D, Bartoces M, Marek J, Stone N, Hicks L, et al. Potential utility of pharmacy data to measure antibiotic use in nursing homes. Infection Control and Hospital Epidemiology. 2019;40(7):819-820. https://doi.org/10.1017/ice.2019.95
60. Karavolias J, Salois M, Baker K, Watkins K. Raised without antibiotics: impact on animal welfare and implications for food policy. Translational Animal Science. 2018;2(4):337-348. https://doi.org/10.1093/tas/txy016
61. Kariuki S, Kering K, Wairimu C, Onsare R, Mbae C. Antimicrobial resistance rates and surveillance in sub-Saharan Africa: where are we now? Infection and Drug Resistance. 2022;15:3589-3609. https://doi.org/10.2147/idr.s342753
62. Katwyk S, Grimshaw J, Nkangu M, Nagi R, Mendelson M, Taljaard M, et al. Government policy interventions to reduce human antimicrobial use: a systematic review and evidence map. PLOS Medicine. 2019;16(6):e1002819. https://doi.org/10.1371/journal.pmed.1002819
63. Keck N, Treilles M, Gordoncillo M, Ivette O, Dauphin G, Dorado-García A, et al. A systematic approach

toward progressive improvement of national antimicrobial resistance surveillance systems in food and agriculture sectors. Frontiers in Veterinary Science. 2023;9. https://doi.org/10.3389/fvets.2022.1057040

64. Kim B, Kim H, Oh M. Antibiotic control policies in South Korea, 2000-2013. Infection and Chemotherapy. 2016;48(3):151. https://doi.org/10.3947/ic.2016.48.3.151
65. Kissler S, Klevens R, Barnett M, Grad Y. Distinguishing the roles of antibiotic stewardship and reductions in outpatient visits in generating a 5-year decline in antibiotic prescribing. Clinical Infectious Diseases. 2020;72(9):1568-1576. https://doi.org/10.1093/cid/ciaa269
66. Kumar S, Chandrasekaran A, Harish B, Roy G, Malini A, Sujatha S. Antimicrobial resistance in India: a review. Journal of Natural Science, Biology and Medicine. 2013;4(2):286. https://doi.org/10.4103/0976-9668.116970
67. Lahra M, Martín I, Demczuk W, Jennison A, Lee K, Nakayama S, et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain. Emerging Infectious Diseases. 2018;24(4). https://doi.org/10.3201/eid2404.171873
68. Liu N, Guan H, Niu G, Jiang L, Li Y, Zhang J, et al. Molecular mechanism of mureidomycin biosynthesis activated by introduction of an exogenous regulatory gene ssaa into Streptomyces roseosporus. Science China Life Sciences. 2021;64(11):1949-1963. https://doi.org/10.1007/s11427-020-1892-3
69. Lv B, Zhou Z, Xu G, Yang D, Wu L, Shen Q, et al. Knowledge, attitudes and practices concerning self-medication with antibiotics among university students in western China. Tropical Medicine & International Health. 2014;19(7):769-779. https://doi.org/10.1111/tmi.12322
70. McParland J, Williams L, Gozdzielewska L, Young M, Smith F, MacDonald J, et al. What are the 'active ingredients' of interventions targeting the public's engagement with antimicrobial resistance and how might they work? British Journal of Health Psychology. 2018;23(4):804-819. https://doi.org/10.1111/bjhp.12317
71. Moienzadeh A, Massoud T, Black E. Evaluation of the general public's knowledge, views and practices relating to appropriate antibiotic use in Qatar. International Journal of Pharmacy Practice. 2015;25(2):133-139. https://doi.org/10.1111/ijpp.12233
72. Mouiche M, Moffo F, Akoachere J, Okah-Nnane N, Mapiefou N, Ndze V, et al. Antimicrobial resistance from a one health perspective in Cameroon: a systematic review and meta-analysis. BMC Public Health. 2019;19(1). https://doi.org/10.1186/s12889-019-7450-5
73. Mupfunya C, Qekwana D, Naidoo V. Antimicrobial use practices and resistance in indicator bacteria in communal cattle in the Mnisi community, Mpumalanga, South Africa. Veterinary Medicine and Science. 2020;7(1):112-121. https://doi.org/10.1002/vms3.334
74. Nawafleh H, Momani M, Hadid L, Amarat W. Misuse of antibiotic therapy among university community in south Jordan. Health Science Journal. 2017;10(6). https://doi.org/10.21767/1791-809x.1000478
75. Nellums L, Thompson H, Holmes A, Castro-Sánchez E, Otter J, Nørredam M, et al. Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2018;18(7):796-811. https://doi.org/10.1016/s1473-3099(18)30219-6.
76. Nkosi B, Sibanda S. Evaluating an antimicrobial stewardship programme implemented in an intensive care unit of a large academic hospital, using the RE-AIM framework. South African Medical Journal. 2021;111(8):777. https://doi.org/10.7196/samj.2021.v111i8.15363
77. Nováková R, Rehakova A, Kutas P, Feckova L, Kormanec J. The role of two SARP family transcriptional regulators in regulation of the auricin gene cluster in Streptomyces aureofaciens CCM 3239. Microbiology. 2011;157(6):1629-1639. https://doi.org/10.1099/mic.0.047795-0
78. Oberin M, Badger S, Faverjon C, Cameron A, Bannister-Tyrrell M. Electronic information systems for one health surveillance of antimicrobial resistance: a systematic scoping review. BMJ Global Health. 2022;7(1):e007388. https://doi.org/10.1136/bmjgh-2021-007388
79. Obi ES, Devdat LNU, Ehimwenma NO, Tobalesi O, Iklaki W, Arslan F. Immune thrombocytopenia: a rare adverse event of vancomycin therapy. Cureus. 2023;15(5).
80. Obi ES, Devdat LNU, Ehimwenma NO, Tobalesi O, Iklaki W, Arslan F, et al. Immune thrombocytopenia: a rare adverse event of vancomycin therapy. Cureus. 2023;15(5).
81. Odionu CS, Ibeh CV. Big data analytics in healthcare: a comparative review of USA and global use cases. International Journal of Multidisciplinary Research and Growth Evaluation. 2023;4(6):1109-1117. https://doi.org/10.54660/.IJMRGE.2023.4.6.1109-1117
82. Ogunboye I, Adebayo IPS, Anioke SC, Egwuatu EC, Ajala CF, Awuah SB. Enhancing Nigeria's health surveillance system: a data-driven approach to epidemic preparedness and response. World Journal of Advanced Research and Reviews. 2023;20(1). https://doi.org/10.30574/wjarr.2023.20.1.2078
83. Ogundairo O, Ayo-Farai O, Maduka CP, Okongwu CC, Babarinde AO, Sodamade OT. Review on MALDI mass spectrometry and its application in clinical research. International Medical Science Research Journal. 2023;3(3):108-126.
84. Ogundairo O, Ayo-Farai O, Maduka CP, Okongwu CC, Babarinde AO, Sodamade O. Review on protein footprinting as a tool in structural biology. Science Heritage Journal (GWS). 2023;7(2):83-90.
85. Ogungbenle HN, Omowole BM. Chemical, functional and amino acid composition of periwinkle (Tympanotonus fuscatus var. radula) meat. International Journal of Pharmaceutical Sciences Review and Research. 2012;13(2):128-132.
86. Ogyu A, Chan O, Littmann J, Pang H, Xia L, Liu P, et al. National action to combat AMR: a one-health approach to assess policy priorities in action plans. BMJ Global Health. 2020;5(7):e002427. https://doi.org/10.1136/bmjgh-2020-002427
87. Okolie CI, Hamza O, Eweje A, Collins A, Babatunde GO. Leveraging digital transformation and business analysis to improve healthcare provider portal. IRE Journals. 2021;4(10):253-254.

https://doi.org/10.54660/IJMRGE.2021.4.10.253-254

88. Onah S, Umar H. Appraising Nigeria's approach to combating antimicrobial resistance. The International Journal of Health Planning and Management. 2023;39(2):556-562. https://doi.org/10.1002/hpm.3717
89. Otto S, Haworth-Brockman M, Miazga-Rodriguez M, Wierzbowski A, Saxinger L. Integrated surveillance of antimicrobial resistance and antimicrobial use: evaluation of the status in Canada (2014–2019). Canadian Journal of Public Health. 2022;113(1):11-22. https://doi.org/10.17269/s41997-021-00600-w
90. Overton K, Fortané N, Broom A, Raymond S, Gradmann C, Orubu E, et al. Waves of attention: patterns and themes of international antimicrobial resistance reports, 1945–2020. BMJ Global Health. 2021;6(11):e006909. https://doi.org/10.1136/bmjgh-2021-006909
91. Pakyz A, Moczygemba L, VanderWielen L, Edmond M, Stevens M, Kuzel A. Facilitators and barriers to implementing antimicrobial stewardship strategies: results from a qualitative study. American Journal of Infection Control. 2014;42(10):S257-S263. https://doi.org/10.1016/j.ajic.2014.04.023
92. Paul PO, Abbey ABN, Onukwulu EC, Agho MO, Louis N. Integrating procurement strategies for infectious disease control: best practices from global programs. Prevention. 2021;7:9.
93. Peng D, Wang X, Xu Y, Sun C, Zhou X. Antibiotic misuse among university students in developed and less developed regions of China: a cross-sectional survey. Global Health Action. 2018;11(1):1496973. https://doi.org/10.1080/16549716.2018.1496973
94. Pierce J, Apisarnthanarak A, Schellack N, Cornistein W, Al-Maani A, Adnan S, et al. Global antimicrobial stewardship with a focus on low- and middle-income countries: a position statement for the International Society for Infectious Diseases. International Journal of Infectious Diseases. 2020;96:621-629. https://doi.org/10.1016/j.ijid.2020.05.126
95. Poomchaichote T, Kiatying-Angsulee N, Boonthaworn K, Naemiratch B, Ruangkajorn S, Praparsavath R, et al. Embedding community and public voices in co-created solutions to mitigate antimicrobial resistance (AMR) in Thailand using the 'responsive dialogues' public engagement framework. Research Square Preprints. 2023. https://doi.org/10.1101/2023.10.06.23296658
96. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathogens and Global Health. 2015;109(7):309-318. https://doi.org/10.1179/2047773215Y.0000000030
97. Rodríguez-Baño J, Rossolini GM, Schultsz C, Tacconelli E, Murthy S, Ohmagari N, et al. Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2021;115(10):1122-1129.
98. Rouusounides A, Papaevangelou V, Hadjipanayis A, Panagakou S, Theodoridou M, Syrogiannopoulos G, et al. Descriptive study on parents' knowledge, attitudes and practices on antibiotic use and misuse in children with upper respiratory tract infections in Cyprus. International Journal of Environmental Research and Public Health. 2011;8(8):3246-3262. https://doi.org/10.3390/ijerph8083246
99. Sakagianni A, Koufopoulou C, Feretzakis G, Kalles D, Verykios V, Myrianthefs P, et al. Using machine learning to predict antimicrobial resistance—a literature review. Antibiotics. 2023;12(3):452. https://doi.org/10.3390/antibiotics12030452
100. Schiaffino F, Colston J, Olórtegui M, Pinedo S, Babilonia M, Asayag C, et al. Antibiotic use and stewardship practices in a pediatric community-based cohort study in Peru: shorter would be sweeter. Clinical Infectious Diseases. 2022;76(3):e1054-e1061. https://doi.org/10.1093/cid/ciac500.
101. Schnall J, Rajkhowa A, Ikuta K, Rao P, Moore C. Surveillance and monitoring of antimicrobial resistance: limitations and lessons from the GRAM project. BMC Medicine. 2019;17(1). https://doi.org/10.1186/s12916-019-1412-8
102. Sharma G, Mutua F, Deka R, Shome R, Bandyopadhyay S, Shome B, et al. A qualitative study on antibiotic use and animal health management in smallholder dairy farms of four regions of India. Infection Ecology & Epidemiology. 2020;10(1). https://doi.org/10.1080/20008686.2020.1792033
103. Sumpradit N, Wongkongkathep S, Malathum K, Janejai N, Paveenkittiporn W, Yingyong T, et al. Thailand's national strategic plan on antimicrobial resistance: progress and challenges. Bulletin of the World Health Organization. 2021;99(09):661–73. https://doi.org/10.2471/blt.20.280644
104. Sumpradit N, Wongkongkathep S, Malathum K, Janejai N, Paveenkittiporn W, Yingyong T, et al. Thailand's national strategic plan on antimicrobial resistance: progress and challenges. Bulletin of the World Health Organization. 2021;99(09):661–73. https://doi.org/10.2471/blt.20.280644
105. Thuy N, Vu H, Nguyen C, Punpuing S, Khan W, Gyapong M, et al. Community-based antibiotic access and use in six low-income and middle-income countries: a mixed-method approach. The Lancet Global Health. 2021;9(5):e610–9. https://doi.org/10.1016/s2214-109x(21)00024-3
106. Timbrook T, Hurst J, Bosso J. Impact of an antimicrobial stewardship program on antimicrobial utilization, bacterial susceptibilities, and financial expenditures at an academic medical center. Hospital Pharmacy. 2016;51(9):703–11. https://doi.org/10.1310/hpj5109-703
107. Turner P, Fox-Lewis A, Shrestha P, Dance D, Wangrangsimakul T, Cusack T, et al. Microbiology investigation criteria for reporting objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data. BMC Medicine. 2019;17(1). https://doi.org/10.1186/s12916-019-1301-1
108. Uwumiro F, Nebuwa C, Nwevo CO, Okpujie V, Osemwota O, Obi ES, et al. Cardiovascular event predictors in hospitalized chronic kidney disease (CKD) patients: a nationwide inpatient sample analysis. Cureus. 2023;15(10).
109. Walia K, Madhumathi J, Veeraraghavan B, Chakrabarti A, Kapil A, Ray P, et al. Establishing antimicrobial resistance surveillance & research network in India. The Indian Journal of Medical Research. 2019;149(2):164–79. https://doi.org/10.4103/ijmr.ijmr_226_18
110. Wernli D, Jørgensen P, Morel C, Carroll S, Harbarth S, Levrat N, et al. Mapping global policy discourse on

antimicrobial resistance. BMJ Global Health. 2017;2(2):e000378. https://doi.org/10.1136/bmjgh-2017-000378
111. Widayati A, Suryawati S, Crespigny C, Hiller J. Knowledge and beliefs about antibiotics among people in Yogyakarta City Indonesia: a cross-sectional population-based survey. Antimicrobial Resistance and Infection Control. 2012;1(1):38. https://doi.org/10.1186/2047-2994-1-38
112. Willemsen A, Reid S, Assefa Y. A review of national action plans on antimicrobial resistance: strengths and weaknesses. Antimicrobial Resistance and Infection Control. 2022;11(1). https://doi.org/10.1186/s13756-022-01130-x
113. Willemsen A, Reid S, Assefa Y. A review of national action plans on antimicrobial resistance: strengths and weaknesses. Antimicrobial Resistance and Infection Control. 2022;11(1). https://doi.org/10.1186/s13756-022-01130-x
114. Zingg W, Storr J, Park B, Jernigan J, Harbarth S, Grayson M, et al. Broadening the infection prevention and control network globally; 2017 Geneva IPC-think tank (part 3). Antimicrobial Resistance and Infection Control. 2019;8(1). https://doi.org/10.1186/s13756-019-0528-0.